Lv11
60 积分 2022-08-11 加入
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
2小时前
待确认
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
14天前
已完结
Prevalence of KRAS Amplification in Patients with Metastatic Cancer: Real-world Next-Generation Sequencing Analysis
14天前
已完结
HER2 and Breast Cancer — A Phenomenal Success Story
16天前
已完结
Small molecule HDAC inhibitors: Promising agents for breast cancer treatment
20天前
已完结
Discovery of novel pyridazine derivatives as glucose transporter type 4 (GLUT4) translocation activators
22天前
已完结
Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer
22天前
已完结
Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit
23天前
已完结
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
25天前
已完结
Abstract OT3-08-01: A phase 1 trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer (aBC) and other solid tumors (PIKASSO-01, trial in progress)
25天前
已关闭
皖公网安备34019202002308
